HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options    My Account    Help    

Portfolio Tracker
Get an update on your stocks every day. See earnings revisions, new reports and Zacks Rank changes at a glance. Click here to learn more.
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Equity Research
My Portfolio
Stock Screener
Profit Tracks
Mutual Funds
Options
Zacks Video
RSS Feed
Profit from the Pros

Subscription Services
Top 10 Stocks
Product Guide
Zacks Premium
Zacks Elite
Method for Trading
Chart Patterns Trader
Double Your Money
ETF Trader
Growth Trader
Options Trader
Small Cap Trader
Strategic Investor
Surprise Trader
Value Trader
Special Reports
Research Wizard

Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive


BVF: Biovail Corp - Stock Quote Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Quote |  Detailed Quotes |  Real Time |  Options Chain |  Greeks Montage

BIOVAIL CORP (NYSE)
BVF 13.94 N/A (N/A%) Vol.  0 N/A ET

Day Low - High N/A - N/A
52wk Low - High 9.26 - 16.14
Avg Volume 1,246,760
Industry MED-DRUGS
Market Cap 2.21 B
Div - Yield 0.36 - 2.58
PE (forward) 10.55
PEG Ratio 1.41
Current Year Est. 1.32
EPS Last Year 1.41
Detailed Quote


Premium Research: Stock Analysis

Zacks Rank

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
# 1Buy12%
# 2Strong Sell50.23%
# 3Hold14%
# 4Sell3.97%
# 5Hold1.85%
S&P50012.22%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


upgraded 02/03/2010
Short-Term Rating 1-3 Months
PREMIUM
Zacks Recommendation

Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.

The Zacks Recommendations are split into 3 groups: Outperform, Neutral and Underperform. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock. More on these reports below.

Difference Between Zacks Rank and Zacks Recommendation
Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations


Long-Term Rating 6+ Months
PREMIUM
Zacks Industry Rank

Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.

When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

About Zacks Industry Rank
Zacks Industry Rank - All current industry ranks.
Zacks Premium - The only way to get access to the Zacks Industry Rank

PREMIUM
Target Price

The Zacks Price Target provides you our expectation for a stocks share price in the next 6 months. These price targets are created by the Zacks Equity Research group to coincide with their recommendations that are also based on a 6 month time horizon.

Zacks Equity Research Home
Zacks Premium - The only way to get access to the Zacks Price Targets

PREMIUM
Equity Research Report

The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

Zacks Equity Research Home Zacks Premium - The only way to get access to Zacks Recommendations


Updated as of 02/03/2010
PREMIUM
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium

Premium Research: Industry Analysis

Top Peers Ticker Zacks Rank
BIOVAIL CORP BVF PREMIUM
PAIN THERAPEUT PTIE PREMIUM
SANTARUS INC SNTS PREMIUM
SUPERGEN INC SUPG PREMIUM
See all MED-DRUGS Peers

BROKERAGE RECOMMENDATIONS
Current ABR 1.50
ABR (Last Week) 1.50
# of Recs in ABR 13
Average Target Price 16.58
Industry Rank by ABR 84 out of 217
Rank in Industry 34 out of 98
More Brokerage Recommendations

Zacks Community PeopleAndPicks.com
Community Rating

PeopleAndPicks.com Community Stock Ratings

Rating Recommendation % of Stocks
5 stars Strong Buy 10%
4 stars Buy 20%
3 stars Hold 40%
2 stars Sell 20%
1 stars Strong Sell 10%
0 stars Not Rated  

We believe that a community of investors working together can create a superior stock rating system. Some call this "collective intelligence". Or simply...together we can beat the market!

A stock's Community Rating is calculated based on the aggregate input of the PeopleAndPicks Community. The proportion of buy to sell ratings, recency of analysis, and the average score of the users who rate it favorably all factor into a score of one to five stars.


How do you rate BVF?
Buy
Sell
Find out what the Zacks Community
thinks of BVF at PeopleAndPicks.com

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

 Interactive Java Charting
 Comparative Chart



 
ZACKS COMMENTARY FOR BVF
Zacks Equity Research: Report for BVF
Feb 03, 2010
Zacks Blog: Zacks #5 Rank Additions for Monday
Feb 01, 2010
Zacks Blog: Zacks #5 Rank Additions for Wednesday
Jan 06, 2010
Zacks Blog: Biovail Enters Oversold Territory
Oct 22, 2009
Zacks Blog: Zacks #1 Rank Additions for Thursday
Oct 22, 2009
Zacks Blog: Zacks #1 Rank Additions for Tuesday
Oct 20, 2009
Zacks Blog: Biovail Continues with Pimavanserin
Oct 14, 2009
Zacks Blog: Biovail to develop Parkinson Drug
Aug 24, 2009
More Zacks Commentary
NEWS
Biovail Enters into License and Collaboration Agreement with Alexza for AZ-004
Feb 10, 2010
Alexza and Biovail Form Collaboration to Develop and Commercialize AZ-004 (Staccato(R) Loxapine) in North America
Feb 10, 2010
BiomedReports: News and FDA Updates for Access (OTC:ACCP), Biovail (NYSE:BVF), Columbia (Nasdaq:CBRX)
Jan 25, 2010
Biovail Comments on Proposed Generic Wellbutrin XL(R) Trial
Jan 22, 2010
MedGenesis Announces Agreements With Amgen and Biovail
Jan 12, 2010
MedGenesis Announces Agreements With Amgen and Biovail
Jan 12, 2010
Biovail to Address JPMorgan Healthcare Conference
Jan 08, 2010
BiomedReports: News and FDA Updates for Biovail (NYSE:BVF), Catalyst Health (NASDAQ:CHSI), Celgene (NASDAQ:CELG)
Jan 07, 2010
More News
EARNINGS ESTIMATES
  This Quarter
12/2009
Next Quarter
03/2010
This Year
12/2009
Next Year
12/2010
Average Estimate 0.40 0.36 1.29 1.32
Number of Estimates 8 3 9 12
Low Estimates 0.31 0.28 1.00 1.01
High Estimate 0.58 0.43 1.41 1.83
Year Ago EPS 0.34 0.41 1.49 1.29
EPS Growth 16.91% -12.20% -13.65% 2.66%

More Estimates

COMPANY DESCRIPTION
Biovail Corporation is a specialty pharmaceutical company, engaged in the formulation, clinical testing, registration, manufacture and commercialization of pharmaceutical products utilizing advanced drug-delivery technologies. Biovail's position of leadership as an innovative developer of medicines is based on its use of advanced drug- delivery technologies that provide significant therapeutic advantages over existing formulations. The Company has a number of proprietary drug-delivery platforms that can be applied to existing in-market drugs to develop enhanced formulations that offer more consistent drug release, greater patient compliance and, potentially, superior efficacy and lower incidence of side effects.

Full Company Report
FINANCIALS
EPS TTM 1.41
Sales 757.18
Net Income 223.84
Price/Earnings 9.89
Price/Book 1.71
Price/Cash Flow 6.47
Price/Sales 2.9


More Financials

 
About Zacks | Advertise | Affiliate | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2010 Zacks Investment Research